ArticleThe British journal of radiology2022
Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression.
Article in The British journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Validating the biological origin of in vivo fractional intracellular volume from VERDICT-MRI in the prostate.European radiology experimental · 2026Observational
- Inter- and intra-rater variability of MRI-based lesion size measurements in active surveillance for prostate cancer: a multicentre study.European radiology · 2026Article
- Article
- Standardizing Prostate MRI Reporting in Active Surveillance for Prostate Cancer: The PRECISE Framework.Journal of the Korean Society of Radiology · 2025Review
- Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value.The Journal of urology · 2025Article
- Biparametric MRI in prostate cancer during active surveillance: is it safe?European radiology · 2024Review
- The role of magnetic resonance imaging in prostate cancer patients on active surveillance.The British journal of radiology · 2023Article
- Stability of Multi-Parametric Prostate MRI Radiomic Features to Variations in Segmentation.Journal of personalized medicine · 2023Article
- Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance.European radiology · 2023Article
- The current role of MRI for guiding active surveillance in prostate cancer.Nature reviews. Urology · 2022Review
- Innovations in prostate cancer: introductory editorial.The British journal of radiology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
objectiveTo analyse serial changes in MRI-derived tumour measurements and apparent diffusion coefficient (ADC) values in prostate cancer (PCa) patients on active surveillance (AS) with and without histopathological disease progression.
methodsThis study included AS patients with biopsy-proven PCa with a minimum of two consecutive MR examinations and at least one repeat targeted biopsy. Tumour volumes, largest axial two-dimensional (2D) surface areas, and maximum diameters were measured on
results60 patients (30 progressors and 30 non-progressors) were included. In progressors,
conclusionAS patients show significant differences in tumour measurements and ADC values between those with and without histopathological disease progression. ADVANCES IN KNOWLEDGE: This paper proposes specific clinical cut-offs for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.